SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful launch of its BlueBird-6 satellite, a critical milestone signifying the company's transition toward commercial scalability for direct-to-device broadband. The community is buzzing with excitement, anticipating significant future growth and contract announcements, though some express caution regarding valuation and a potential "sell the news" reaction. This event firmly positions ASTS as a major player in the rapidly evolving space-based cellular network industry.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers. The community is actively discussing a potential 'silver squeeze' and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is a major talking point with significant anticipation surrounding its upcoming showcases of commercial quantum computing solutions at industry events. The community is deeply divided, with many optimistic about the company's potential for broad adoption and future partnerships, while a vocal segment expresses caution regarding valuation and recent executive stock sales. This reflects broader market debate on the commercial readiness and investment risks within the evolving quantum computing sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is a major talking point following its announced inclusion in the S&P MidCap 400. This news is generating significant community excitement, anticipating increased institutional demand, enhanced visibility, and a potential short squeeze. Investors are highlighting its strong financial position and its critical role in the rapidly evolving agentic AI and automation sector as key drivers for future growth.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending on widespread anticipation for the FDA's decision on Narsoplimab, a first-in-class drug for TA-TMA, with many speculating on an early approval before the December 26th PDUFA date. The community is actively discussing potential for a significant price surge fueled by high unmet medical need, strong trial data, and the recent $2.1 billion Novo Nordisk deal that has bolstered Omeros's financial position. This binary event has triggered intense debate over short manipulation and a possible "shakeout" of shares ahead of what many believe will be a transformative approval.

Starfighters Space Inc

Starfighters Space Inc. (FJET), a recently public aerospace company, is trending due to extreme volatility driven by its low float and very high short interest. The community is fiercely divided, with many anticipating a significant short squeeze while others label it a pump-and-dump. There is widespread discussion about alleged market manipulation influencing its price action amidst this speculative fervor.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending following its acquisition by Sanofi, prompting widespread congratulatory messages among shareholders and discussions around the valuation of the deal. The acquisition, which enhances Sanofi's vaccine portfolio with Dynavax's Hepatitis B vaccine and shingles treatment, also fuels conversations regarding the implications for Vaxart due to their oral COVID-19 vaccine licensing agreement. This development provides a significant exit for long-term investors amid prior frustrations concerning management and shareholder value.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid mixed signals, with community frustration mounting over its stock performance despite positive developments. While initial discussion revolved around rumors of Nvidia abandoning Intel's 18A process, the recent clearance of Nvidia's $5 billion investment in Intel and the company's partnership in the US Department of Energy's "Genesis Mission" for AI are fueling optimism among long-term bulls regarding its advanced foundry initiatives and US government support.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is trending due to multiple strategic partnerships focused on deploying its advanced thin-film solar technology across aerospace, defense, and terrestrial applications. The community is actively discussing the stock's significant price and volume surges, viewing it as a high-potential speculative play driven by the burgeoning space economy and demand for resilient power in extreme environments.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing significant buzz driven by substantial new orders for its 800G transceivers from hyperscale customers, positioning the company as a key enabler in the expanding AI-driven data center market. The community is actively discussing strong bullish signals, including notable institutional interest and positive analyst upgrades, with many anticipating a significant long-term growth trajectory for its high-speed optical solutions. This strong momentum highlights AAOI's critical role in supporting the next generation of AI infrastructure amid broader sector growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Fitch believes companies with portfolios focused on oncology, immunology, rare diseases, vaccines and metabolic or weight‑management therapies are likely to outgrow the market.&nbsp;</li><li>The firm deems policy risk, particularly regarding drug pricing, as high.&nbsp;</li><li>Fitch now expects global pharma revenue growth to be around 3.2% in 2026.&nbsp;</li></ul><p>Fitch Ratings said on Tuesday that it expects mid-single-digit growth in global medicines spending in 2026, supported by an aging population and broadening access to healthcare.</p><p>The global pharma sector’s operating environment will remain stable supporting a ‘neutral’ outlook, Fitch Ratings <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fitchratings.com/research/corporate-finance/global-pharmas-2026-demand-growth-resilient-a-test-year-for-margins-23-12-2025">said</a>, while adding that companies with portfolios focused on oncology, immunology, rare diseases, vaccines and metabolic or weight‑management therapies are likely to outgrow the market.</p><h2 class="st-heading-2">Policy Risks</h2><p>Fitch, however, flagged risks including policy uncertainty testing operating profitability. Fitch deems policy risk, particularly regarding drug pricing, as high.</p><p>“In the US, the Most Favoured Nation pricing framework, potential import tariffs and evolving pharmacy benefit manager access dynamics are likely to increase pricing dispersion and cost volatility in 2026,” it said. “Issuers with diversified portfolios, domestic manufacturing options and inventory flexibility should preserve rating headroom despite policy volatility.”</p><p>Fitch now expects global pharma revenue growth to be around 3.2% in 2026, below the 5.3% expected in 2025. The base case for revenue growth is underpinned by innovation and volume increases in chronic and specialty categories, it said. Players with specialized therapeutic depth and broad modality exposure are better positioned to sustain above-market trajectories, Fitch added.</p><h2 class="st-heading-2">M&amp;A Activity In 2026</h2><p>The firm now sees merger and acquisition activity to remain elevated in 2026, extending the 2025 rebound in biotech dealmaking that outdid 2024 levels. It also expects a sustained rise in capital expenditure as companies regionalize manufacturing and invest in complex biologics and cell and gene platforms.</p><h2 class="st-heading-2">Trump’s Most Favored Pricing Deals</h2><p>Last week, U.S. President Trump<a href="https://stocktwits.com/news-articles/markets/equity/trump-strikes-new-drug-price-deals-with-roche-novartis-merck-and-other-pharma-giants/cLe0duBREtP"> announced</a> nine new agreements with pharma companies to lower prescription drug prices for Americans to levels paid in other developed nations. Overall, 14 pharma companies have now inked similar deals with the administration in return for pharma tariff reprieve and expedited drug application reviews including Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, Pfizer, Eli Lilly and Sanofi.</p><p>The S&amp;P Pharmaceuticals Select Industry Index has gained about 31% this year while the Dow Jones U.S. Pharmaceuticals Index gained over 24%.</p><p>Large-cap pharma stocks like Eli Lilly, Johnson &amp; Johnson, and Merck have all gained single to double digit stock growth this year while Pfizer fell 6%.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-confirms-death-of-patient-enrolled-in-hemophilia-drug-study/cLepu4KREHO">Pfizer Confirms Death Of Patient Enrolled In Hemophilia Drug Study</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Young female scientist working in laboratory (Representative image courtesy of Solskin via Getty Images)

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk

The firm also expects merger and acquisition activity in the sector to remain elevated in 2026. 

Equity

GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages

Shares of GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) have been given a consensus recommendation of "Hold" by the eight research firms that are covering the stock, MarketBeat.com reports. Two...

Wendy Becker Acquires 441 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK - Get Free Report) insider Wendy Becker purchased 441 shares of the business's stock in a transaction that occurred on Friday, December 19th. The shares were bought at an average...

GSK (LON:GSK) Insider Purchases 7,977.69 in Stock

GSK plc (LON:GSK - Get Free Report) insider Wendy Becker bought 441 shares of the stock in a transaction on Friday, December 19th. The stock was purchased at an average cost of GBX 1,809 per share...

Insider Buying: GSK (LON:GSK) Insider Purchases 1,650 Shares of Stock

GSK plc (LON:GSK - Get Free Report) insider Jonathan Symonds purchased 1,650 shares of the company's stock in a transaction dated Monday, December 22nd. The stock was purchased at an average cost of...

US Medicaid Program Will Hit Swiss Wallets Hard, Roche CEO Says

Roche CEO predicts higher drug costs in Switzerland due to U.S. government's deals with pharmaceutical companies.read more...

Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals

Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.

Samsung Biologics To Acquire GSK's Rockville Facility For US$280 Mln

(RTTNews) - Samsung Biologics (207940.KS) announced that its wholly owned U.S. subsidiary, Samsung Biologics America, will acquire 100% of Human Genome Sciences from GSK (GSK, GSK.L) for US$280...

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic...

Douglas Lane & Associates LLC Sells 196,210 Shares of GSK PLC Sponsored ADR $GSK

Douglas Lane & Associates LLC cut its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 14.9% during the third quarter, according to its most recent disclosure with the Securities...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK
Glaxosmithkline plc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GSK News

GSKGlaxosmithkline plc - ADR